MIT Device Solves Cell Settling
MIT researchers have developed MagMix, a magnetic mixer that prevents cells from settling in bioprinter syringes for over 45 minutes. This simple hardware solution addresses a major challenge in long-duration prints, ensuring uniform cell distribution for more consistent production of cell therapies or other biologics.
The work on MagMix was led by Dr. Ritu Raman, the Eugene Bell Career Development Professor of Tissue Engineering at MIT, and Ferdows Afghah, a postdoc in mechanical engineering. Their research, published in the journal *Device*, addresses the critical issue of cell settling in bio-inks, a long-standing obstacle in scaling up the production of engineered tissues. Cell settling during lengthy print jobs leads to clogged nozzles, inconsistent cell distribution, and ultimately, variable tissue quality. Existing methods to mitigate this, such as manual stirring or passive mixers, are often insufficient once the printing process begins. This inconsistency is a major bottleneck, hindering the reliable production of large or complex tissues for applications in disease modeling and drug discovery. The MagMix system utilizes a small magnetic propeller inside the bioprinter syringe, controlled by an external motorized magnet. This setup allows for gentle, real-time mixing that can be adjusted for different bio-ink viscosities, ensuring cells remain evenly suspended without inducing significant stress. Computer simulations were used to optimize the propeller's geometry and rotation speed before experimental validation. In testing, MagMix successfully prevented cell settling for over 45 minutes of continuous printing across various bio-ink types, maintaining high cell viability. As a proof-of-concept, the team printed cells that later matured into muscle tissue, demonstrating the functional viability of the process. This low-cost, compact device can be retrofitted onto any standard 3D bioprinter. This type of hardware innovation is crucial for the industrialization of cell and gene therapies, where process automation and consistency are paramount for GMP environments. By ensuring uniform cell distribution, technologies like MagMix support the development of robust, scalable manufacturing platforms and facilitate the transition to electronic batch records (EBRs) by providing more consistent process data. The broader context is a cell and gene therapy CDMO market projected to grow significantly, reaching an estimated $74.03 billion by 2034. However, the sector faces challenges, including a recent pullback in biotech funding and underutilization of CDMO capacity. Innovations that improve manufacturing reliability and scalability are key to overcoming these hurdles and meeting the rising demand, with over 60 gene therapies expected to gain approval by 2030. As biotech manufacturing increasingly incorporates AI and machine learning for process optimization, the data generated from more consistent and automated systems becomes invaluable. Digital twins and predictive models rely on high-quality data to improve yields and ensure product quality, and hardware that eliminates process variability is a foundational element for these advanced digital systems. This advance aligns with the FDA's growing interest in alternatives to animal testing, as more reliable bioprinting can produce higher-fidelity human tissue models for safety and efficacy studies. The work received support from MIT's Safety, Health, and Environmental Discovery Lab (SHED), which focuses on translating lab innovations into scalable, practical tools.
